Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:35:50 2025-01-21 am EST			5-day change	1st Jan Change
89.50 ^CHF	+0.30%		-0.77%	+0.81%

Jan. 20	NOVARTIS AG : Jefferies remains Neutral	ZD
Jan. 17	Sector Update: Health Care Stocks Rise Premarket Friday	MT

A poor 2024 increases the odds of a brighter 2025

January 02, 2025 at 08:40 am EST

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novartis AG

NOVARTIS AG : Jefferies remains Neutral	Jan. 20	ZD
Sector Update: Health Care Stocks Rise Premarket Friday	Jan. 17	MT
Novartis Obtains Temporary Court Order Blocking Generic Version of Entresto	Jan. 17	MT
US appeals court lifts pause on generic version of Novartis' Entresto	Jan. 16	RE
Novartis Wins Temporary Stay on Heart Failure Drug's Generic Version in US	Jan. 16	MT
Novartis loses emergency bid to block Entresto generic in US	Jan. 15	RE
Healthcare stocks 'a good place to be,' portfolio manager says	Jan. 14	RE
Novartis AG Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 08:15 AM	Jan. 14
Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	Jan. 13	MT
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	Jan. 13
Illumina Starts Pilot Program With Partners to Generate Proteomics Data	Jan. 13	MT
Novartis: Favourable court ruling on Entresto	Jan. 13	CF
Novartis's U.S. Patent for Entresto Upheld by Appeals Court	Jan. 13	DJ
US Court Upholds Validity of Novartis' Combination Patent for Entresto	Jan. 13	MT
Novartis Entresto(R) US patent upheld by US Court of Appeals	Jan. 13	DJ
NOVARTIS AG : Goldman Sachs remains Neutral	Jan. 09	ZD
Light Horse Therapeutics Inc announced that it expects to receive $87 million in funding from Versant Venture Management, LLC, Bristol-Myers Squibb Company, AbbVie Ventures, Inc., Taiho Ventures, LLC, Mubadala Capital, Novartis AG	Jan. 08	CI
NOVARTIS AG : Gets a Neutral rating from Berenberg	Jan. 07	ZD
NOVARTIS AG : Bernstein reiterates its Buy rating	Jan. 07	ZD
A poor 2024 increases the odds of a brighter 2025	Jan. 02
Experts expect more IPOs and takeovers in 2025	Jan. 02	RE
Swiss Stocks Close Higher Ahead of New Year Break	Dec. 30	MT
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2025-01-31 - Q4 2024 Earnings Release

More about the company